Featured
Advertisement
-
-
KRAS degradation averts PDAC chemoresistance
Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.
-
-
Trending - Altmetric
-
Lipids as mediators of cancer progression and metastasis
-
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy
-
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells
-
Trans-Atlantic twists and turns